scispace - formally typeset
Search or ask a question
Journal ArticleDOI

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010

Theo Vos, Abraham D. Flaxman1, Mohsen Naghavi1, Rafael Lozano1  +360 moreInstitutions (143)
15 Dec 2012-The Lancet (Elsevier)-Vol. 380, Iss: 9859, pp 2163-2196
TL;DR: Prevalence and severity of health loss were weakly correlated and age-specific prevalence of YLDs increased with age in all regions and has decreased slightly from 1990 to 2010, but population growth and ageing have increased YLD numbers and crude rates over the past two decades.
About: This article is published in The Lancet.The article was published on 2012-12-15 and is currently open access. It has received 7021 citations till now. The article focuses on the topics: Years of potential life lost & Global health.
Citations
More filters
Journal ArticleDOI
TL;DR: Whether the loss of nutrients associated with disc degeneration limits the effectiveness of biologic approaches is discussed, and it is indicated that this neglected problem requires investigation if clinical application of such therapies is to succeed.
Abstract: Strategies for the biological repair of intervertebral discs derive from the premise that disc degeneration results from impaired cellular activity and, therefore, that these structures can be induced to regenerate by implanting active cells or providing factors that restore normal cellular activity. In vitro and animal studies using this approach have had some success, but whether this success can be reproduced in degenerate human lumbar discs is unknown. Successful repair requires that the disc cells remain viable and active; they therefore need an adequate supply of nutrients. However, as the disc degenerates, the nutrient supply decreases, thereby limiting cell activity and viability. Current biologic approaches might place additional demands on an already precarious nutrient supply. Here, we discuss whether the loss of nutrients associated with disc degeneration limits the effectiveness of biologic approaches, and indicate that this neglected problem requires investigation if clinical application of such therapies is to succeed.

228 citations

Journal ArticleDOI
TL;DR: Stratified care for back pain implemented in family practice leads to significant improvements in patient disability outcomes and a halving in time off work, without increasing health care costs.
Abstract: PURPOSE We aimed to determine the effects of implementing risk-stratified care for low back pain in family practice on physician’s clinical behavior, patient outcomes, and costs. METHODS The IMPaCT Back Study (IMplementation to improve Patient Care through Targeted treatment) prospectively compared separate patient cohorts in a preintervention phase (6 months of usual care) and a postintervention phase (12 months of stratified care) in family practice, involving 64 family physicians and linked physical therapy services. A total of 1,647 adults with low back pain were invited to participate. Stratified care entailed use of a risk stratification tool to classify patients into groups at low, medium, or high risk for persistent disability and provision of risk-matched treatment. The primary outcome was 6-month change in disability as assessed with the Roland-Morris Disability Questionnaire. Process outcomes captured physician behavior change in risk-appropriate referral to physical therapy, diagnostic tests, medication prescriptions, and sickness certifications. A cost-utility analysis estimated incremental quality-adjusted life-years and back-related health care costs. Analysis was by intention to treat. RESULTS The 922 patients studied (368 in the preintervention phase and 554 in the postintervention phase) had comparable baseline characteristics. At 6 months follow-up, stratified care had a small but significant benefit relative to usual care as seen from a mean difference in Roland-Morris Disability Questionnaire scores of 0.7 (95% CI, 0.1–1.4), with a large, clinically important difference in the high risk group of 2.3 (95% CI, 0.8–3.9). Mean time off work was 50% shorter (4 vs 8 days, P = .03) and the proportion of patients given sickness certifications was 30% lower (9% vs 15%, P = .03) in the postintervention cohort. Health care cost savings were also observed. CONCLUSIONS Stratified care for back pain implemented in family practice leads to significant improvements in patient disability outcomes and a halving in time off work, without increasing health care costs. Wider implementation is recommended.

228 citations

Journal ArticleDOI
TL;DR: Advances in cell and molecular therapy, including mobilisation and activation of endogenous progenitor cells, progenitors cell homing, and targeted delivery of cells, genes, or bioactive factors are discussed are discussed.

227 citations

Journal ArticleDOI
TL;DR: A large number of the questioned patients had prior musculoskeletal conditions and the results confirmed the need for further research into these conditions to determine their prognosis.
Abstract: Lead Authors Anthony Woolf, Bone and Joint Research Group, Royal Cornwall Hospital, UK; Chair, Global Alliance for Musculoskeletal Health Lyn March, Institute of Bone and Joint Research, University of Sydney, Australia; Chair, Global Alliance for Musculoskeletal Health Surveillance & Information Task Force; Member, International Coordinating Committee Alana Officer, Senior Health Advisor, Department of Ageing and Life Course, WHO International Core Writing Group Marita J Cross*, Institute of Bone and Joint Research, University of Sydney, Australia. Andrew M Briggs*, School of Physiotherapy & Exercise Science, Curtin University, Australia; Arthritis and Osteoporosis Victoria, Australia. Damian Hoy, Global Alliance for Musculoskeletal Health Surveillance & Information Task Force, Secretariat of the Pacific Community. Lidia Sanchez-Riera, Centre on Aging and Mobility, University of Zürich and City Hospital Waid Zurich, Switzerland. Fiona Blyth, Concord Clinical School, University of Sydney, Australia

226 citations

Journal ArticleDOI
TL;DR: There is not enough in vivo evidence to support the efficiency of antioxidant supplementation to retard the process of IDD, so further investigations based on in vivo and clinical studies will be required to develop effective antioxidative therapies for IDD.
Abstract: Excessive reactive oxygen species (ROS) generation in degenerative intervertebral disc (IVD) indicates the contribution of oxidative stress to IVD degeneration (IDD), giving a novel insight into the pathogenesis of IDD. ROS are crucial intermediators in the signaling network of disc cells. They regulate the matrix metabolism, proinflammatory phenotype, apoptosis, autophagy, and senescence of disc cells. Oxidative stress not only reinforces matrix degradation and inflammation, but also promotes the decrease in the number of viable and functional cells in the microenvironment of IVDs. Moreover, ROS modify matrix proteins in IVDs to cause oxidative damage of disc extracellular matrix, impairing the mechanical function of IVDs. Consequently, the progression of IDD is accelerated. Therefore, a therapeutic strategy targeting oxidative stress would provide a novel perspective for IDD treatment. Various antioxidants have been proposed as effective drugs for IDD treatment. Antioxidant supplementation suppresses ROS production in disc cells to promote the matrix synthesis of disc cells and to prevent disc cells from death and senescence in vitro. However, there is not enough in vivo evidence to support the efficiency of antioxidant supplementation to retard the process of IDD. Further investigations based on in vivo and clinical studies will be required to develop effective antioxidative therapies for IDD.

224 citations

References
More filters
Journal ArticleDOI
Rafael Lozano1, Mohsen Naghavi1, Kyle J Foreman2, Stephen S Lim1  +192 moreInstitutions (95)
TL;DR: The Global Burden of Diseases, Injuries, and Risk Factors Study 2010 aimed to estimate annual deaths for the world and 21 regions between 1980 and 2010 for 235 causes, with uncertainty intervals (UIs), separately by age and sex, using the Cause of Death Ensemble model.

11,809 citations

Book
31 Dec 1997
TL;DR: The aim of this study was to establish a database of histological groups and to provide a level of consistency and quality of data that could be applied in the design of future registries.
Abstract: 1. Techniques of registration 2. Classification and coding 3. Histological groups 4. Comparability and quality of data 5. Data processing 6. Age-standardization 7. Incidence data by site and sex for each registry 8. Summary tables presenting age-standardized rates 9. Data on histological type for selected sites

10,160 citations

Journal ArticleDOI
18 Jun 2003-JAMA
TL;DR: Notably, major depressive disorder is a common disorder, widely distributed in the population, and usually associated with substantial symptom severity and role impairment, and while the recent increase in treatment is encouraging, inadequate treatment is a serious concern.
Abstract: ContextUncertainties exist about prevalence and correlates of major depressive disorder (MDD).ObjectiveTo present nationally representative data on prevalence and correlates of MDD by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, and on study patterns and correlates of treatment and treatment adequacy from the recently completed National Comorbidity Survey Replication (NCS-R).DesignFace-to-face household survey conducted from February 2001 to December 2002.SettingThe 48 contiguous United States.ParticipantsHousehold residents ages 18 years or older (N = 9090) who responded to the NCS-R survey.Main Outcome MeasuresPrevalence and correlates of MDD using the World Health Organization's (WHO) Composite International Diagnostic Interview (CIDI), 12-month severity with the Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR), the Sheehan Disability Scale (SDS), and the WHO disability assessment scale (WHO-DAS). Clinical reinterviews used the Structured Clinical Interview for DSM-IV.ResultsThe prevalence of CIDI MDD for lifetime was 16.2% (95% confidence interval [CI], 15.1-17.3) (32.6-35.1 million US adults) and for 12-month was 6.6% (95% CI, 5.9-7.3) (13.1-14.2 million US adults). Virtually all CIDI 12-month cases were independently classified as clinically significant using the QIDS-SR, with 10.4% mild, 38.6% moderate, 38.0% severe, and 12.9% very severe. Mean episode duration was 16 weeks (95% CI, 15.1-17.3). Role impairment as measured by SDS was substantial as indicated by 59.3% of 12-month cases with severe or very severe role impairment. Most lifetime (72.1%) and 12-month (78.5%) cases had comorbid CIDI/DSM-IV disorders, with MDD only rarely primary. Although 51.6% (95% CI, 46.1-57.2) of 12-month cases received health care treatment for MDD, treatment was adequate in only 41.9% (95% CI, 35.9-47.9) of these cases, resulting in 21.7% (95% CI, 18.1-25.2) of 12-month MDD being adequately treated. Sociodemographic correlates of treatment were far less numerous than those of prevalence.ConclusionsMajor depressive disorder is a common disorder, widely distributed in the population, and usually associated with substantial symptom severity and role impairment. While the recent increase in treatment is encouraging, inadequate treatment is a serious concern. Emphasis on screening and expansion of treatment needs to be accompanied by a parallel emphasis on treatment quality improvement.

7,706 citations

Book
01 Jan 1996
TL;DR: This is the first in a planned series of 10 volumes that will attempt to "summarize epidemiological knowledge about all major conditions and most risk factors" and use historical trends in main determinants to project mortality and disease burden forward to 2020.
Abstract: This is the first in a planned series of 10 volumes that will attempt to "summarize epidemiological knowledge about all major conditions and most risk factors;...generate assessments of numbers of deaths by cause that are consistent with the total numbers of deaths by age sex and region provided by demographers;...provide methodologies for and assessments of aggregate disease burden that combine--into the Disability-Adjusted Life Year or DALY measure--burden from premature mortality with that from living with disability; and...use historical trends in main determinants to project mortality and disease burden forward to 2020." This first volume includes chapters summarizing results from the project as a whole. (EXCERPT)

7,154 citations

Related Papers (5)
Jes Olesen, André Bes, Robert S. Kunkel, James W. Lance, Giuseppe Nappi, V Pfaffenrath, Frank Clifford Rose, Bruce S. Schoenberg, D. Soyka, Peer Tfelt-Hansen, K. Michael A. Welch, Marica Wilkinson, Marie-Germaine Bousser, Hans-Christoph Diener, David W. Dodick, Michael First, Peter J. Goadsby, Hartmut Göbel, Miguel J. A. Láinez, Richard B. Lipton, Fumihiko Sakai, Jean Schoenen, Stephen D. Silberstein, Timothy J. Steiner, Lars Bendtsen, Anne Ducros, Stefan Evers, Andrew D. Hershey, Zaza Katsarava, Morris Levin, Julio Pascual, Michael Bjørn Russell, Todd J. Schwedt, Cristina Tassorelli, Gisela M. Terwindt, Maurice Vincent, Shuu Jiun Wang, Andrew Charles, R. Lipton, Hayrunnisa Bolay, Michel Lantéri-Minet, E. A. Macgregor, T. Takeshima, Henrik Winther Schytz, S. Ashina, M. T. Goicochea, K. Hirata, Kenneth A. Holroyd, Christian Lampl, Dimos-Dimitrios Mitsikostas, P. Goadsby, C. Boes, C. Bordini, E. Cittadini, Andrew I. Cohen, M. Leone, A. May, L. Newman, J. Pareja, J. W. Park, T. Rozen, E. Waldenlind, Jong Ling Fuh, Aynur Özge, J. A. Pareja, Mario Fernando Prieto Peres, William B. Young, S. Y. Yu, Ishaq Abu-Arafeh, J. Gladstone, S. J. Huang, Rigmor Jensen, J.M. Láinez, D. Obelieniene, Peter S. Sandor, A. I. Scher, Marcel Arnold, Martin Dichgans, E. Houdart, José M. Ferro, Elizabeth Leroux, Y. S. Li, Aneesh B. Singhal, Gretchen E. Tietjen, Deborah I. Friedman, S. Kirby, B. Mokri, A. Purdy, K. Ravishankar, W. Schievink, R. Stark, F. Taylor, A. V. Krymchantowski, A. Tugrul, N. J. Wiendels, E. Marchioni, V. V. Osipova, Lidia Savi, J. R. Berger, Marcelo E. Bigal, J. González Menacho, Federico Mainardi, J. Pereira-Monteiro, M. Serrano-Dueñas, Roger Cady, C. Fernandez de las Peñas, Vincenzo Guidetti, J. Lance, Peter Svensson, Elizabeth Loder, A. E. Lake, Françoise Radat, J. I. Escobar, R. Benoliel, Claudia Sommer, A. Woda, Joanna M Zakrzewska, V. Aggarwal, L. Bonamico, Dominik A Ettlin, S. Graff-Radford, Jean-Paul Goulet, S. Jääskeläinen, Volker Limmroth, Ambra Michelotti, Donald R. Nixdorf, Mark Obermann, Richard Ohrbach, Paul Pionchon, Tara Renton, S. De Siqueira, Çiçek Wöber-Bingöl